Compare STN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STN | IOVA |
|---|---|---|
| Founded | 1954 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 6.7B |
| IPO Year | 2005 | 2008 |
| Metric | STN | IOVA |
|---|---|---|
| Price | $72.21 | $8.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.40 |
| AVG Volume (30 Days) | 270.0K | ★ 12.3M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.97 | $56.63 |
| Revenue Next Year | $5.63 | $43.83 |
| P/E Ratio | $28.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.35 | $1.76 |
| 52 Week High | $111.02 | $15.37 |
| Indicator | STN | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.72 | 29.97 |
| Support Level | $71.90 | $7.85 |
| Resistance Level | $73.03 | $9.36 |
| Average True Range (ATR) | 1.57 | 0.98 |
| MACD | 0.49 | -0.75 |
| Stochastic Oscillator | 87.77 | 1.76 |
Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.